The New England journal of medicine
-
Randomized Controlled Trial Multicenter Study
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
In a phase 2 study, the inhibition of the interleukin-17A receptor improved signs and symptoms of psoriatic arthritis. We sought to evaluate the efficacy and safety of secukinumab, an anti-interleukin-17A monoclonal antibody, in such patients. ⋯ Secukinumab was more effective than placebo in patients with psoriatic arthritis, which validates interleukin-17A as a therapeutic target. Infections were more common in the secukinumab groups than in the placebo group. The study was neither large enough nor long enough to evaluate uncommon serious adverse events or the risks associated with long-term use. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT01392326.).
-
Randomized Controlled Trial Multicenter Study
Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy.
The role of trypanocidal therapy in patients with established Chagas' cardiomyopathy is unproven. ⋯ Trypanocidal therapy with benznidazole in patients with established Chagas' cardiomyopathy significantly reduced serum parasite detection but did not significantly reduce cardiac clinical deterioration through 5 years of follow-up. (Funded by the Population Health Research Institute and others; ClinicalTrials.gov number, NCT00123916; Current Controlled Trials number, ISRCTN13967269.).